Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05372679 · ClinicalTrials.gov registry record · NA
REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /
A NA study of Uncontrolled Stage 2 Hypertension, sponsored by SoniVie.
- Active
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 9
- Study locations
NCT05372679 is a NA study of Uncontrolled Stage 2 Hypertension that is active but no longer recruiting, run by SoniVie. The registered enrollment target is 25 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT05372679, a NA study of Uncontrolled Stage 2 Hypertension, is active but no longer recruiting, sponsored by SoniVie.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a prospective, multicenter, non-randomized, open-label clinical study of the safety and performance of the TIVUS™ System in subjects with uncontrolled stage 2 hypertension in order to assess the safety and effectiveness of the TIVUS™ System when used for renal artery denervation. The study will assess the acute and chronic safety of the procedure as well as the reduction in 24-hour ambulatory mean systolic blood pressure from baseline to 3 months after the procedure.
Conditions Studied
Interventions
- DEVICE Renal denervation
Study Locations (9)
Arkansas
- ST Bernards Medical Center - Jonesboro
- Arkansas Heart Hospital - Little Rock
Alabama
- Cardiology P.C. - Birmingham
Connecticut
- Bridgeport Hospital - Bridgeport
Illinois
- Prairie Education and Research Cooperative - Springfield
Minnesota
- Minneapolis Heart Institution Foundation - Minneapolis
New York
- Columbia University/NYPH - New York
North Carolina
- NC Heart and Vascular Research, LLC - Raleigh
South Carolina
- Medical University South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2025-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05372679
The ClinicalTrials.gov registry entry for NCT05372679 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SoniVie, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uncontrolled Stage 2 Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Renal denervation is the first listed.
NCT05372679 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Arkansas, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05372679 about?
NCT05372679 is a clinical study titled "REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /". This is a prospective, multicenter, non-randomized, open-label clinical study of the safety and performance of the TIVUS™ System in subjects with uncontrolled stage 2 hypertension in order to assess the safety and effectiveness of the TIVUS™ System when used for renal artery denervation. The study w...
What is the current status of trial NCT05372679?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2022-11-11. Estimated completion is 2025-12.
What conditions does trial NCT05372679 study?
This clinical trial studies the following conditions: Uncontrolled Stage 2 Hypertension.
What interventions are being tested in trial NCT05372679?
The interventions under investigation include: Renal denervation (DEVICE).
Who is sponsoring clinical trial NCT05372679?
This trial is sponsored by SoniVie, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05372679 being conducted?
This trial has 9 study locations across Alabama, Arkansas, Connecticut, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.